Author

Tanushree Banerjee

Associate Professor, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune, India - Cited by 351 - Molecular Biology - Neurobiology

Biography

Tanushree Banerjee currently works at Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune. Tanushree does research in Biotechnology, Cell Biology and Molecular Biology. Currently, the lab is working on understanding the role of glucose metabolism and insulin signaling in neurodegeneration. Skills and Expertise:Insulin Resistance,Glucose Metabolism Disorders,Neurodegeneration,COVID-19.  
Title
Cited by
Year
Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase
G Kumar, P Parasuraman, SK Sharma, T Banerjee, K Karmodiya, ...Journal of medicinal chemistry 50 (11), 2665-2675, 2007200
111
2007
Formulation of nanotized curcumin and demonstration of its antimalarial efficacy
A Ghosh, T Banerjee, S Bhandary, A SuroliaInternational journal of nanomedicine, 5373-5387, 2014201
42
2014
SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl‐acyl carrier protein reductase
G Kumar, T Banerjee, N Kapoor, N Surolia, A SuroliaIUBMB life 62 (3), 204-213, 2010201
26
2010
Apicoplast triose phosphate transporter (TPT) gene knockout is lethal for Plasmodium
T Banerjee, DK Jaijyan, N Surolia, AP Singh, A SuroliaMolecular and biochemical parasitology 186 (1), 44-50, 2012201
23
2012
Benzothiophene carboxamide derivatives as inhibitors of Plasmodium falciparum enoyl‐ACP reductase
T Banerjee, SK Sharma, N Kapoor, V Dwivedi, N Surolia, A SuroliaIUBMB life 63 (12), 1101-1110, 2011201
22
2011
An in silico scientific basis for LL‐37 as a therapeutic for Covid‐19
An in silico scientific basis for LL‐37 as a therapeutic for Covid‐KB Lokhande, T Banerjee, KV Swamy, P Ghosh, M DeshpandeProteins: Structure, Function, and Bioinformatics 90 (5), 1029-1043, 2022202
19
2022
Epigallocatechin gallate is a slow-tight binding inhibitor of Enoyl-ACP Reductase from Plasmodium falciparum
A Banerjee, T., Sharma, S. K., Surolia, N., SuroliaBBRC 277, 1238-1242, 200818200
18
2008
Design, development, synthesis, and docking analysis of 2′‐substituted triclosan analogs as inhibitors for Plasmodium falciparum Enoyl‐ACP reductase
N Kapoor, T Banerjee, P Babu, K Maity, N Surolia, A SuroliaIUBMB life 61 (11), 1083-1091, 2009200
16
2009
Benzothiophene carboxamide derivatives as novel antimalarials
T Banerjee, N Kapoor, N Surolia, A SuroliaIUBMB life 63 (12), 1111-11, 2011201
15
2011
15‐deoxyspergualin hinders physical interaction between basic residues of transit peptide in PfENR and Hsp70‐1
T Banerjee, RR Singh, S Gupta, A Surolia, N SuroliaIUBMB life 64 (1), 99-107, 202
12
2012
Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients
PG Kulkarni, A Sakharkar, T BanerjeeHypertension Research 45 (2), 254-269, 2022202
10
2022
Insulin signaling pathway protects neuronal cell lines by Sirt3 mediated IRS2 activation
N Mishra, S Lata, P Deshmukh, K Kamat, A Surolia, T BanerjeeBiofactors 44 (3), 224-236, 2018201
10
2018
Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from plasmodium falciparum
K Maity, T Banerjee, N Prabakaran, N Surolia, A Surolia, K SugunaIUBMB life 63 (1), 30-41, 2011201
8
2011
Nanotized curcumin‐benzothiophene conjugate: A potential combination for treatment of cerebral malaria
A Ghosh, T BanerjeeIUBMB life 72 (12), 2637-260, 2020202
5
2020
Benzothiophene carboxamide compounds, composition and applications thereof
A Surolia, T Banerjee, N Surolia, N KapoorUS Patent App. 13/183,04, 010
2
2012

Referred From: https://scholar.google.co.in/citations?user=gCtCKU0AAAAJ&hl=en

Cited by
Citations 351
h-index 11
i10-index 13
Open Access Journals